Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Tara Perloff"'
Autor:
Divij Mathew, Laura A. Vella, Randall A. Oyer, Jedd D. Wolchok, James Robinson, Cécile Alanio, Susan DeWolf, Kara N. Maxwell, Amy E. Baxter, Erin Bange, Karan Naik, Scott E. Hensley, Justin Kim, Anita Kumar, Tara Perloff, Adam J Widman, Madison E. Weirick, Santosha Vardhana, Madeline A Hwee, Florence Porterfield, Derek A. Oldridge, Krista R Budzik, Samuel J Kerr, Justine V. Cohen, Nicholas Han, Josephine R. Giles, Christopher M McAllister, Ariel R. Weisman, Michael Galantino, Angela DeMichele, Ivan Maillard, Charlotte Roberts, Caroline A. G. Ittner, Paul Wileyto, Ronac Mamtani, Lova Sun, Susan Tollett, Jennifer E. Wu, Olutosin Owoyemi, Sharon Adamski, John P. Reilly, Alexander C. Huang, Sigrid Gouma, Ryan Massa, Allison R. Greenplate, Sawsan R. Boutemine, E. John Wherry, Heather M. Giannini, Tiffanie K. Jones, Carla Wright, Olutwatosin Oniyide, Emily M. Kugler, N. Esther Babady, Alfred L. Garfall, Peter Maslak, Robert H. Vonderheide, Cathy Zheng, R.S. Agyekum, Nuala J. Meyer, Thomas G. Dunn
Publikováno v:
Nature Medicine. 27:1280-1289
Patients with cancer have high mortality from coronavirus disease 2019 (COVID-19), and the immune parameters that dictate clinical outcomes remain unknown. In a cohort of 100 patients with cancer who were hospitalized for COVID-19, patients with hema
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::953c384aa17e1a2d15af5f6dd7fec305
https://doi.org/10.1038/s41591-021-01386-7
https://doi.org/10.1038/s41591-021-01386-7
Publikováno v:
J Psychosoc Oncol
Objectives: Historically, long-term survival following diagnosis of lung cancer has been a rare occurrence. An overall poor prognosis and the low likelihood of long-term survival are though...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17eee21eb0c2b210c05602b8c2c247e1
https://doi.org/10.1080/07347332.2019.1569191
https://doi.org/10.1080/07347332.2019.1569191
Publikováno v:
Journal of Thoracic Oncology. 13:S380-S381
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed69b4c8169e91a15ca2b3f26a4661dd
https://doi.org/10.1016/j.jtho.2018.08.374
https://doi.org/10.1016/j.jtho.2018.08.374
Publikováno v:
Journal of Clinical Oncology. 37:10535-10535
10535 Background: The expanding armamentarium of immunotherapies available to treat patients with cancer poses a challenge to community practitioners. They need guidance around the practical issues that they must navigate to provide immunotherapy saf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::50365dfdac230ff1146d83200fe779c0
https://doi.org/10.1200/jco.2019.37.15_suppl.10535
https://doi.org/10.1200/jco.2019.37.15_suppl.10535
Autor:
Ivo Abraham, Jennie R. Crews, Monique Dawkins, Jeffrey P. Gregg, Tara Perloff, Lee S. Schwartzberg
Publikováno v:
Journal of Clinical Oncology. 37:80-80
80 Background: The Association of Community Cancer Centers (ACCC) Immuno-Oncology Institute was developed in 2015 to prepare all members of the multidisciplinary cancer care team for the complex implementation of immuno-oncology in the community sett
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::91229acad12997e74a1ca5a1a2f7480e
https://doi.org/10.1200/jco.2019.37.8_suppl.80
https://doi.org/10.1200/jco.2019.37.8_suppl.80
Publikováno v:
Journal of Clinical Oncology. 37:87-87
87 Background: The rapidly expanding indications for cancer immunotherapies pose a significant challenge to community clinicians to integrate this new class of agents into practice. Community cancer centers need guidance around the practical issues t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::18bf4c5a2020e9a449ebdfcb42ca5f7b
https://doi.org/10.1200/jco.2019.37.8_suppl.87
https://doi.org/10.1200/jco.2019.37.8_suppl.87
Publikováno v:
Journal of Clinical Oncology. 37:98-98
98 Background: Survivorship care plans are a key piece of coordinated, patient-centered care delivery. As with other cancer treatment modalities, patients with metastatic disease who achieve durable benefit with immunotherapy (IO) treatment may exper
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::451e4912de78fb3437ae89c04a7c10bb
https://doi.org/10.1200/jco.2019.37.8_suppl.98
https://doi.org/10.1200/jco.2019.37.8_suppl.98
Publikováno v:
Journal of Thoracic Oncology. 12:S1438-S1439
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d238108fe5d5b21c9ed37294af9dea95
https://doi.org/10.1016/j.jtho.2016.11.2205
https://doi.org/10.1016/j.jtho.2016.11.2205
Autor:
Tara Perloff, W. Turell, Jeffrey P. Gregg, Dan J. Raz, Jennie R. Crews, L. Lucas, P. Rattananont
Publikováno v:
Journal of Thoracic Oncology. 13:S825
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b16a24301900f9f1e89c53e8a8a869e
https://doi.org/10.1016/j.jtho.2018.08.1462
https://doi.org/10.1016/j.jtho.2018.08.1462